CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer®
CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the appointment of Dr. Malte Greune as Chief Operating Officer (COO) effective July 1, 2021. In this position, he will strengthen the company’s Management Board and will head, among others, CureVac’s clinical and commercial manufacturing activities. Dr. Greune joins CureVac with extensive experience in the global pharmaceutical industry, including manufacturing of vaccines and fill & finish of biologics.